Ubrigene (Beijing) Biology Technology Co., Ltd. (“Ubrigene”) has recently completed its Series C financing in the hundreds of millions RMB. The round was led by the National Strategic Transformation and Upgrading Fund under Jingshi Investment, Jingshi Kangjian Fund, and Lyon Capital's flagship China market USD fund. Also participating were Huada Gongying, Xing Investment Capital, Wenzhou Investment, Yuan Chuang Capital, as well as existing shareholders, including Huagai Capital, Fangfu Capital, and IDG Capital.

CEC Capital served as the exclusive financial advisor to Ubrigene in this transaction.

This latest financing will further accelerate Ubrigene's global expansion and expedite the establishment of CMC research and development centers in the United States and Canada. The company is propelling its advancements in CGT vector technologies and methodologies, fortifying Ubrigene's premier stance in offering comprehensive CDMO services for CGT. The raised capital will also be channeled into bolstering production capacities for a wide array of products such as GMP AAV, plasmids, lentiviruses, and CAR-T. Ubrigene's vision is clear: catalyze the evolution and industry-wide adoption both domestically and internationally.

Founded in 2015, Ubrigene is dedicated to providing one-stop CDMO services for CGT and constructing a robust GMP manufacturing base in China. Since its launch in March 2022, Ubrigene's Suzhou CDMO facility has operated steadily and established strategic partnerships with multiple clients. The Suzhou facility covers an area of 9,000 square meters and is equipped with advanced process development and production workshops, as well as multiple GMP production lines. It offers eukaryotic cell culture scales ranging from 50L to 2000L and prokaryotic fermentation scales from 10L to 200L. Additionally, it is equipped with advanced purification processes to support gene therapy companies comprehensively.